GSK (LON:GSK) Given New GBX 2,100 Price Target at Citigroup

GSK (LON:GSK) had its target price dropped by equities researchers at Citigroup from GBX 2,250 to GBX 2,100 in a report issued on Wednesday,Digital Look reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s target price would suggest a potential upside of 11.73% from the company’s previous close.

Several other equities research analysts have also recently weighed in on GSK. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research note on Thursday, March 26th. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. UBS Group reissued a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a research note on Friday, January 23rd. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Tuesday, April 14th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of GBX 2,034.29.

GSK Price Performance

Shares of GSK stock opened at GBX 1,879.50 on Wednesday. The stock has a market cap of £75.12 billion, a price-to-earnings ratio of 13.23, a PEG ratio of 1.24 and a beta of 0.35. The business’s fifty day moving average is GBX 2,077.02 and its 200 day moving average is GBX 1,929.05. GSK has a twelve month low of GBX 1,288.61 and a twelve month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The company had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Research analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In other news, insider Wendy Becker acquired 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The shares were bought at an average cost of GBX 1,963 per share, with a total value of £78,520. Also, insider Jonathan Symonds acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were purchased at an average cost of GBX 1,951 per share, for a total transaction of £97,550. Over the last 90 days, insiders purchased 15,452 shares of company stock valued at $32,135,952. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.